Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,277
  • Shares Outstanding, K 28,567
  • Annual Sales, $ 920 K
  • Annual Income, $ -10,720 K
  • 60-Month Beta 1.82
  • Price/Sales 59.32
  • Price/Cash Flow N/A
  • Price/Book 4.11
Trade NAVB with:

Options Overview

Details
  • Implied Volatility 122.43%
  • Historical Volatility 57.22%
  • IV Percentile 7%
  • IV Rank 9.88%
  • IV High 417.79% on 07/09/20
  • IV Low 90.03% on 05/08/20
  • Put/Call Vol Ratio 1.84
  • Today's Volume 347
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 7,236
  • Open Int (30-Day) 2,185

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6400 +3.05%
on 04/12/21
2.4000 -29.58%
on 03/16/21
-0.5100 (-23.18%)
since 03/12/21
3-Month
1.6400 +3.05%
on 04/12/21
3.1500 -46.35%
on 02/09/21
-0.5900 (-25.88%)
since 01/13/21
52-Week
0.6300 +168.25%
on 04/16/20
5.3569 -68.45%
on 07/21/20
+0.9250 (+120.92%)
since 04/13/20

Most Recent Stories

More News
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 24, 2021 / Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 24, 2021...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 1.6900 (-2.87%)
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the...

NAVB : 1.6900 (-2.87%)
New Strong Sell Stocks for December 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

BVN : 10.65 (+0.47%)
NAVB : 1.6900 (-2.87%)
STAF : 0.7433 (-1.67%)
WTER : 1.0400 (-1.89%)
PROS : 12.65 (-0.24%)
Navidea Biopharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12,...

NAVB : 1.6900 (-2.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 1.7802
2nd Resistance Point 1.7501
1st Resistance Point 1.7201
Last Price 1.6900
1st Support Level 1.6600
2nd Support Level 1.6299
3rd Support Level 1.5999

See More

52-Week High 5.3569
Fibonacci 61.8% 3.5512
Fibonacci 50% 2.9935
Fibonacci 38.2% 2.4357
Last Price 1.6900
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar